Victor Weigman, Ph.D. | August 30, 2017

Leveraging RNA-Seq for a robust, accurate measure of HLA calling for endpoints in clinical trials

Presentation from The 2017 Immuno-Oncology Summit In Boston, MA
Presented at The Immuno-Oncology Summit in August, 2017, this presentation highlights HLA typing in immunotherapy trials, including advantages and difficulties as well as types of HLA typing. This presentation also provides the benefits of HLAProfiler.

Victor Weigman, Ph.D., Director, Translational Genomics

Related Services:
Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Planning and implementing biomarker testing for immuno-oncology trials

Exploring the challenges with the diverse clinical biomarker requirements

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More